Education
BA Degree, Vanderbilt University, Nashville, TN Sept. 1970
- Dec. 1973
MD Degree, University of Oklahoma School of Medicine
Oklahoma City, OK; August 1974 - June 1978
Internship in Internal Medicine
University of Oklahoma Health Sciences Center
Oklahoma City, OK; July 1978 - June 1979
Resident in Neurology
University of Oklahoma Health Sciences Center
Oklahoma City, OK; July 1979 - June 1982
Chief Resident in Neurology
University of Oklahoma Health Sciences Center
Oklahoma City, OK; July 1981 - June 1982
Professional Experience
Neurologic Consultant for United Healthcare (part-time),
February 1, 1999 - current
Epileptologist consultant for the Hammond Development Center, Hammond, LA. (part-time),
January, 2001-current.
Academic Appointments
Assistant Professor of Neurology, University of Oklahoma
School of Medicine, Oklahoma Medical Center, Oklahoma City, OK, July 1, 1982
- June 30, 1997
Associate Professor of Neurology, University of Oklahoma School
of Medicine, Oklahoma Medical Center, Oklahoma City, OK July 1, 1997 - August
1, 1998
Administrative
Medical Director, Neurologic Outpatient Services, University-Presbyterian
Outpatient Clinic, March 1, 1996 - August 1, 1998
Oklahoma Memorial Hospital, Residents Clinic July 1, 1985 - June
30, 1989
Chief of Neurology Service, University Hospital (Oklahoma Memorial Hospital),
May 31, 1990 - August 1, 1998
Medical Director, Oklahoma Center for Neurologic Sciences, University
Hospital, Fall 1985 - Spring 1996
Professional And Scientific
Memberships:
American Medical Association - 1979-1997
Oklahoma State Medical Association - 1980-1997
Oklahoma County Medical Society - 1980-1997
American Academy of Neurology - 1980 - present
Oklahoma Neurological Society - 1985-1998
American Epilepsy Society - 1990
Society for Neuroscience - Oklahoma Chapter - 1994-1998
Southern Clinical Neurological Society - 1996
New Orleans Neurological Society - 1999
Honor Societies
Alpha Lambda Delta - Freshman Women's Honor Society, Vanderbilt
University
Phi Kappa Phi - University of Oklahoma Chapter
The Neurology Development Award - June 30, 1989
Given by the Faculty and Staff of the Department of Neurology - OUHSC
"For Constant Commitment to the Development of Fellow Neurones"
Top-Forty Epilepsy Mini-Fellows Symposium, Bowman Gray, 10/22-10/25/92 (selected
from 800 mini-fellows on basis of test scores and productivity in epilepsy and
epilepsy education)
Selected for inclusion in the first edition of The Best Doctors in America:
Central Region 1996 1997.
Listed in Who's Who in Medicine and Healthcare 1999-2000, Second Edition, June,
1998.
Research Grants And Contracts
An Open-Label Multi-Center Study of The Safety and Efficacy
of Gabapentin As Monotherapy or Add-on Therapy in The Long-term Treatment of
Epileptic Seizures. Protocol for Warner Lambert/Parke-Davis, Fall 1989. (grant
total $51,060.00).
Depakote in The Treatment of Complex Partial Seizures (Protocol
No. M88-194) Sponsored by Abbott Laboratories, Fall 1990. (grant total $60,553.00).
Clinical Experience and Use of Sabril in Patients with Partial
Seizures. Protocol # VG PR0098 for Marion Merrell Dow, Inc. (1994) (grant total
$20,000.00)
Evaluation of The Efficacy and Tolerability of UCB LO59 (500 and 1500mg b.i.d.,
tablets) Add On Treatment in Epileptic Patients With Partial Onset Seizures:
A 38-week double-blind Placebo-controlled parallel group multicenter trial.
Study N132 for UCB S.A. Pharma Sector. (Fall, 1994).(grant total $240,000.00,
or $8,000.00 per patient x 30 patients.)
A One Year Multicenter Follow-up Study of the Safety and Efficacy
of Oral 500 mg Tablets ucb L059 in Patients with Partial Onset Epileptic Seizures:
A 4-week double-blind Titration to 3000 mg/d, Followed by an Open Treatment
Phase at Individualized Doses. Study for UCB S.A. Pharma Sector. (1995-1996).
(grant total $83,840.00).
A Long-term, Open-label, Multicenter Study of the Safety and
Efficacy of ucb L059 (Levetiracetam) 500 mg Tablets at Individualized Oral Doses
Ranging From 1000 mg/day to 4000 mg/day in the Treatment of Epilepsy. Study
N147 for UCB S.A. Pharma Sector. (1996).
Safety and Efficacy of High Versus Low Dose Oxcarbazepine Monotherapy
in Patients with Uncontrolled Partial Onset Seizures. (Protocol #47680-02-026
for Ciba-Geigy) 1995. (grant total $56,000.00)
Multicenter, Long-Term Extension Phase of Oxcarbazepine Trial
#47680-02-026E in Patients with Uncontrolled Partial-Onset Seizures. Trial Phase
III sponsored by Ciba-Geigy, 1995.
Adjunctive Lamictal (lamotrigene) in Epilepsy and Response to
Treatment (A.L.E.R.T.). Burroughs Wellcome, phase IV study. (1995)($1400.00)
Neurontin Steps (Study of Titration to Effectiveness and Profile
of Safety). Parke-Davis, phase IV study. (1995)($7,000.00) Co-investigator with
Dr. K.J. Oommen (PI).
Dose-Response Study of Efficacy and Safety of Vigabatrin (Sabril)
1,3,4, and 6g/day as Monotherapy in Patients with Complex Partial Seizures.
(Protocol # 223 for Hoechst Marion Roussel, Inc.) (1995)( Grant total $83,000.00)
An Open-Label, Follow-up, Long-term Maintenance Study of Vigabatrin
(Sabril) As Monotherapy in Patients with Complex Partial Seizures. (Protocol
# 242 for Hoechst Marion Roussel, Inc.) (1995) (grant total $41,800.00).
A Multi-center, Double-blind, Placebo-controlled, Parallel Evaluation
of Lamictal as Add-on Therapy with Valproic Acid for the Treatment of Generalized
Seizures in Pediatric and Adult Patients. Protocol #105-045 sponsored by Glaxo
Wellcome Research and Development. (1996) (Grant total $6600.00/patient). Subinvestigator
with Dr. K.J. Oommen (PI), Dr. Peggy J. Wisdom, and Dr. Julie T. Parke.
Topiramate (RWJ-17021-000) Monotherapy Clinical Trial in Subjects
with Recently Diagnosed Partial-Onset Seizures. (With extension phase.) Sponsored
by the R.W. Johnson Pharmaceutical Research Institute.(1996) (Grant total $27,590).
Subinvestigator with Dr. Terry Rodgers(PI), Dr. KJ Oommen, Dr. Peggy J. Wisdom,
and Dr. Julie T. Parke.
A Multicenter, Double-blind, Placebo-controlled, Randomized,
Stratified, Parallel- group Trial of Rufinamide as Adjunctive Therapy in Children
and Adults with Inadequately Controlled Partial Seizures. (Protocol 3310101021;
Version 4/9/97) Sponsored by Novartis Pharmaceuticals.
Pregabalin Add-on Trial: A Double-Blind, Placebo-Controlled,
Multicenter Study in Patients with Complex Partial Seizures (Protocol 1008-009).($4880/patient).
Pregabalin Add-on Trial: An Open-Label, Multicenter Study to
Determine the Long-Term Safety and Efficacy of Pregabalin in Patients with Complex
Partial Seizures with or without Secondary Generalization (Protocol 1008-010).
($4800/patient).
Publications:
Book Chapters
King JA. Headaches in children. In: Pediatric Neurology
Core Curriculum Syllabus, 1985.
King JA. Chapter 66: Seizures and Epilepsy. In: Kaufman CE and
McKee PA, eds. Essentials of Pathophysiology, Boston: Little, Brown and Company,
1996:719-27.
Articles
Robinson B, Clark RM, King JA, Hurt B, Mohr JA. Chronic
Gambian trypanosomiasis. Southern Medical Journal 1980; 73: 516-18.
Michaelis M, King JA, Leech RW, Min KW, Brumback RA. Perineural
cell ensheathment of muscle fibers: a new syndrome of fatigable muscle weakness
mimicking myasthenia gravis. Clinical Neuropathology 1991; 10:79-84.
Nowack WJ, King JA. Triphasic waves and spike wave stupor. Clinical
EEG 1992; 23:100-104.
Willmore LJ, Shu V, Wallin B, and the M88-194 Study Group. Efficacy
and safety of add-on divalproex sodium in the treatment of complex partial seizures.
Neurology 1996; 46:49-53. (Study Group participant)
Wilder, BJ, ed. Management of epilepsy: Consensus conference
on current clinical practice. Neurology 1998; 51(Suppl. 4) S1-43. (Consensus
group participant)
Cereghino JJ, Biton V, Abou-Khalil B, Dreifuss F, Gauer LJ, Leppik
I, and the United States Levetiracetam Study Group. Levetiracetam for partial
seizures: results of a double-blind, randomized clinical trial. Neurology 2000;55:236-242.
(Study Group participant)
Abou-Khalil B, Trudeau V, Garofalo E, Pierce M, and the
US Gabapentin Study Group 945-15. The long-term safety and efficacy of gabapentin
(Neurontin) as add-on therapy in patients with refractory partial or generalized
seizures. Epilepsy Research. (Study Group participant)
Abstracts
King JA, Justice B, Bodensteiner JB. Progressive facial
hemiatrophy: a review, update and report of CT findings. Presented to the Southern
Child Neurology Society, January 14, 1982.
Michaelis M, King JA, Leech RW, Min K, Brumback RA. Perineural
cell ensheathment of muscle fibers: a new syndrome of fatigable muscle weakness
mimicking myasthenia gravis. Poster presentation at the 42nd Annual Meeting
of the American Academy of Neurology, Miami Beach, Florida, May 4, 1990. Neurology
1990; 40(Suppl 1): S351.
Fodor PA, Wisdom PJ, King JA, and Selby G. Neurotoxicity associated
with VP16-213: a report of four cases with coma. Poster presentation, AOA Day,
October 30, 1991.
King JA. Increased incidence of adverse behavioral side effects
associated with the addition of felbamate to antiepileptic drug regimens in
the mentally retarded population. Poster presentation at the December 1994 Meeting
of American Epilepsy Society. Epilepsia 1994; 35(Suppl 8): S94.
Winegarner DM, King JA, Chacko GN, Oommen KJ. Reflex belly dancing:
comparison of ictal and interictal electroencephalography (EEG) to single photon
emission computed tomography (SPECT) in localization of focus in a novel case
of proprioceptive-induced truncal seizures. Poster presentation at the 4th Annual
Symposium of the Oklahoma Center for Neurosciences, October 2, 1995.
King JA and Bayles RL. Weight gain during add-on therapy using gabapentin (GBP).
Poster presentation at the 1995 Annual Meeting of the American Epilepsy Society
in Baltimore, Maryland; December 5, 1995. Epilepsia 1995; 36(Suppl 4): S72.
King JA, Knight JE, and Oommen KJ. Efficacy of lamotrigine (LTG)
in the developmentally disabled. Poster presentation at the 1996 Annual Meeting
of the American Epilepsy Society in San Francisco, California; December 10,
1996. Epilepsia 1996; 37(Suppl 5): S162.
Chacko GN, D'Souza MF, Oommen KJ, King JA, Prince JR. Interictal
and immediate post-ictal SPECT with Tc-99m ECD in complex partial seizures.
Presented by Dr. Chacko as a platform presentation to the Radiological Society
of North America '96,82nd scientific assembly and meeting.
King JA and Knight JE. Low Incidence of rash associated with
slow titration of lamotrigine (LTG). Poster presentation at the 22nd International
Epilepsy Congress, Dublin, Ireland, June 30, 1997. Epilepsia 1997; 38(Suppl
3): S32.
King JA and Knight JE. Low Incidence of rash associated with slow titration
of lamotrigine (LTG). Poster presentation at the 6th Annual Oklahoma Center
for Neuroscience (OCNS) Symposium, Oklahoma City, Oklahoma, October 17, 1997.
Chacko GN, Turner J, Oommen KJ, King JA, Rodgers-Neame NT, Parrot
D, Coffelt D. Interictal & immediate postictal perfusion patterns using
99M Tc ECD (Neurolite) SPECT in patients with complex partial seizures. Poster
presentation at the 22nd International Epilepsy Congress, Dublin, Ireland, June
30, 1997. Epilepsia 1997; 38(Suppl 3): S10.
Oommen KJ, King JA, Carter LP, Chacko G, and Wilson D. Utility
of combined interictal and immediate postictal SPECT (IISPECT and PISPECT) in
localization of epileptogenic foci using Tc-99m ECD (Neurolite). Poster presentation
at the 1997 Annual Meeting of the American Epilepsy Society in Boston, Massachusetts;
December 9, 1997. Epilepsia 1997; 38(Suppl 8): S146.
Oommen KJ, Chacko GN, King JA, Rodgers-Neame NT, Wilson D, Burow
RD, Parrot D, and Coffelt D. Immediate postictal hypoperfusion in single photon
emission computed tomogram (SPECT): A new localizing finding in partial seizures.
Poster presentation at the 1998 Annual Meeting of the American Epilepsy Society
in San Diego, California; December 7, 1998. Epilepsia 1998; 39(Suppl 6): S79.
King JA, Swann MH, Samuel SR, Richardson SM, Stewart K, and Couch
JR. Long-term weight gain (WG) associated with valproate (VPA) in developmentally
disabled (DD) and normal adults (NA). Poster presentation at the 1998 Annual
Meeting of the American Epilepsy Society in San Diego, California; December
7, 1998. Epilepsia 1998; 39(Suppl 6): S49.
Oommen KJ, Jones H, King JA, Francel P, Reynolds E, and Couch JR. Functional
reorganization in the homunculus: Electrocorticographic evidence. Poster presentation
at the American Clinical Neurophysiology Society Annual Meeting and Courses,
October1-5, 1998, New Orleans, Louisiana. J Clin Neurophysiol 1999; 16:180.
Sachdeo R, Beydoun A, Schachter S, et al. Safety and efficacy
of oxcarbazepine monotherapy [Abstract]. Neurology 1998;50:A200 (Study Group
participant)
Book Reviews
King JA: HEAD INJURY. Edited by Paul R. Cooper, MD, Baltimore:
The Williams and Wilkins Company, 1982. Journal of the Oklahoma State Medical
Association 1983; 76:335-36.
King JA: NEUROLOGIC EMERGENCIES: RECOGNITION AND MANAGEMENT,
SECOND EDITION. Edited by Michael Saleman, MD, F.A.C.S. Raven Press LTD, New
York, 1990, Journal of Child Neurology 1992; 7:124-25.
King JA: SEIZURES AND CONVULSIONS IN INFANTS, CHILDREN AND ADOLESCENTS.
PRACTICAL INFORMATIVE GUIDE FOR PARENTS, TEACHERS AND PARAMEDICAL PERSONNEL.
Leonardo Garcia-Mendez. Lemar Publishers, Columbia, Mo., 1994. Journal of Child
Neurology 1995; 10:341-42.
|
FAQs | Supported By | Epilepsy Links | Contact Us
